NCT00661154已完成不适用
Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 7
- 试验地点
- 1
- 主要终点
- Determine whether[18F]-5-Fluorouracil PET/CT scanning can demonstrate a difference in [18F]-5-Fluorouracil tumor uptake before and after the administration of Avastin
研究概览
简要总结
To determine whether using a radiolabelled analog of 5-FU, [18F]-5-fluorouracil, for PET/CT imaging can visually demonstrate differential chemotherapy delivery to known tumor sites before and after administration of bevacizumab and determine the optimal timing of bevacizumab administration to maximize the chemotherapy delivery into the tumor for improved cancer treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically or cytologically confirmed adenocarcinoma of the colon.
- •Patients must have metastatic disease to the liver with at least one lesion that is measurable by RECIST criteria within 4 weeks prior to entry of study
- •Patients with a history of colon adenocarcinoma treated by surgical resection who develop radiological or clinical evidence of metastatic cancer do not require separate histological or cytological confirmation of metastatic disease unless an interval of > 5 years has elapsed between the primary surgery and the development of metastatic disease. Clinicians should consider biopsy of lesions to establish diagnosis of metastatic colon adenocarcinoma if there is substantial clinical ambiguity regarding the nature or source of apparent metastases.
- •Patients must have ECOG performance status of 0-2
- •Patients must be >= 18 years of age
- •Laboratory values <= 2 weeks prior to enrollment:
- •Absolute Neutrophil Count (ANC) >= 1.5 x 10^9/L (>= 1500/mm^3)
- •Platelets (PLT) >= 100 x 10^9/L >= 100,000/mm^3)
- •Hemoglobin (Hgb) >= 9 g/dL
- •Serum creatinine <= 1.5 ULN
- •Serum bilirubin <= 1.5 ULN
- •Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) <= 3.0 x ULN (<= 5 x ULN if liver metastases present). Note: ERCP or percutaneous stenting may be used to normalize the liver function tests.
- •Negative for proteinuria based on dip stick reading OR, if documentation of +1 result for protein on dip stick reading, then total urinary protein <= 500 mg and measured creatinine clearance (CrCl) >= 50 mL/min from a 24-hour urine collection
- •Life expectancy >= 12 weeks
- •Ability to give written informed consent according to local guidelines
排除标准
- •Patients receiving prior 5-FU for the treatment of metastatic colorectal adenocarcinoma will be excluded from enrollment. Previous use of 5-FU for adjuvant treatment of resected stage II or III colorectal adenocarcinoma will be allowed, provided the time from last 5-FU administration to enrollment is > 3 months.
- •Prior full field radiotherapy <= 4 weeks or limited field radiotherapy <= 2 weeks prior to enrollment. Patients must have recovered from all therapy-related toxicities. The site of previous radiotherapy should have evidence of progressive disease if this is the only site of disease.
- •Prior biologic or immunotherapy <= 2 weeks prior to registration. Patients must have recovered from all therapy-related toxicities
- •Prior therapy with anti-VEGF agents
- •Patients with a history of another primary malignancy <= 5 years, with the exception of inactive basal or squamous cell carcinoma of the skin
- •Concurrent use of other investigational agents and patients who have received investigational drugs <= 4 weeks prior to enrollment.
- •Female patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control. Barrier contraceptives must be used throughout the trial in both sexes. Women of childbearing potential must have a negative serum pregnancy test 48 hours prior to administration of study treatment.
- •Patients unwilling to or unable to comply with the protocol
结局指标
主要结局
Determine whether[18F]-5-Fluorouracil PET/CT scanning can demonstrate a difference in [18F]-5-Fluorouracil tumor uptake before and after the administration of Avastin
时间窗: 1-4 days
次要结局
- Determine if [18F]-5-Fluorouracil PET/CT imaging demonstrates that there is a difference in maximal [18F]-5-Fluorouracil tumor uptake that is dependent on the time point of post-Avastin scanning(1-4 days)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
不适用
Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBMAstrocytoma, Grade IVGiant Cell GlioblastomaGlioblastoma MultiformeNCT00943462Centre hospitalier de l'Université de Montréal (CHUM)
已完成
不适用
Fluorine F 18 EF5 Positron Emission Tomography in Assessing Hypoxia in Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Head or Neck Squamous Cell Cancer of the Oral Cavity, Oropharynx, and LarynxSquamous Cell CarcinomaNCT01020097Abramson Cancer Center at Penn Medicine5
招募中
早期 1 期
18F-Fluciclovine PET-MRI in High-grade GliomaHigh Grade GliomaGlioma, MalignantGlioma IntracranialDiffuse GliomaGliomaNCT05553041Children's Hospital of Philadelphia30
已完成
1 期
Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR CardiomyopathyCardiomyopathies, PrimaryNCT05374564Yale University12
撤回
不适用
18F-fluoride PET-scan as complementary diagnostic medium for patients with otosclerosis - A pilot studyfixation of the stapes1001399510027584otosclerosisNL-OMON36729Medisch Universitair Ziekenhuis Maastricht40